Citius Oncology (CTOR) Preferred Stock Liabilities (2022 - 2024)

Citius Oncology (CTOR) has reported Preferred Stock Liabilities for 3 consecutive years, with $49.2 million the latest figure, recorded in Q2 2024.

• On a quarterly basis, Preferred Stock Liabilities fell 29.16% year-over-year to $49.2 million in Q2 2024; TTM through Jun 2024 was $49.2 million, a 29.16% decrease from a year earlier, with the FY2023 full-year figure at $72.6 million, up 7.01% from the prior year.
• Preferred Stock Liabilities was $49.2 million for Q2 2024 at Citius Oncology, up from $48.3 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $72.6 million in Q4 2023 and troughed at $48.3 million in Q1 2024.
• A 3-year average of $63.8 million and a median of $68.6 million in 2023 frame the typical range for Preferred Stock Liabilities.
• Across the five-year window, Preferred Stock Liabilities advanced 7.01% in 2023 and dropped 29.54% in 2024, its largest moves.
• Over 3 years, Preferred Stock Liabilities stood at $67.8 million in 2022, then gained by 7.01% to $72.6 million in 2023, then tumbled by 32.26% to $49.2 million in 2024.
• The last three Preferred Stock Liabilities figures came in at $49.2 million (Q2 2024), $48.3 million (Q1 2024), and $72.6 million (Q4 2023), per Business Quant data.